RIGImmune is a platform biopharmaceutical company developing a novel investigational class of RNA immunotherapies termed “SLRs” for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The RIGImmune development candidates act to specifically modulate RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The lead development candidate at RIGImmune is RIG-101.
The company was co-founded by the prominent Yale University professors, Anna Marie Pyle, Ph.D. and Akiko Iwasaki, Ph.D., who currently serve as scientific advisors to the company. Dr. Pyle co-discovered the RIG-I receptor family and conducted many of the first structural and biochemical investigations on the cytosolic protein, RIG-I. Dr. Pyle is also a specialist in RNA structure and design. She designed the stem-loop RNA therapeutics (SLR) for selective targeting of RIG-I using crystal structure data of RIG-I complexed with RNA and developed them as antitumor and anticancer compounds in collaboration with Dr. Iwasaki, whose expertise in mucosal immunity has been highly sought during the COVID-19 pandemic.
RIGImmune is a UConn Technology Incubation Program (TIP) company located in Farmington, CT, was founded by Yale scientists, and has an experienced management team of successful biotech entrepreneurs and world-renowned scientists.
Ashby exists to deliver a new standard of recruiting software to enable hiring excellence. It’s all-in-one recruiting platform enables high growth companies to hire more efficiently by combining features for the entire recruiting process, from sourcing to offer, with advanced analytics and automation.
WellBeam transforms workflows between MD teams and their post-acute partners continuing the medical care of their patients. Through its EMR integrated solution, WellBeam reduces home health readmissions, drives provider wellness through less administrative workflow, and captures underbilled CMS codes available to providers.
Judi Health, formerly Capital Rx, is built around the mission of changing the way prescription drugs are priced and patients are serviced. A health technology company daring to reimagine the healthcare industry, Judi Health is executing on that mission with its enterprise pharmacy platform JUDI™, which connects every aspect of the pharmacy ecosystem in one platform, enabling patient engagement and increasing efficiency to achieve the highest standards of clinical care.
Better Life Partners is a provider of high-quality, integrated medical and behavioral healthcare to people not well served by the traditional system. The company’s offerings include group therapy sessions with a special curriculum that utilizes evidence-based cognitive and dialectical behavioral therapy to build a sense of community and purpose toward a better life, enabling patients of substance abuse to be provided with aid and support to get sober.
Latchel is an award-winning property management technology company that empowers property managers to provide unbeatable customer experience with streamlined maintenance operations, and top-tier resident amenities. With built in layers that elevate the resident experience, property managers are also able to increase their revenue by implementing the service as a resident paid amenity. Renters get better service levels that average a 4.8/5 star rating, and property managers can increase both operational efficiency and overall profitability.
Teleo is revolutionizing heavy equipment operations by turning construction and mining equipment into semi-autonomous robots. Their Teleo Supervised Autonomy technology lets contractors operate existing heavy equipment without an operator in the cab, letting a single operator control multiple pieces of equipment from a remote desk. This increases productivity, safety, and operator satisfaction — critical challenges in the construction and mining industries. Teleo is backed by UP.Partners, F-Prime Capital, K9 Ventures, YCombinator and a host of industry luminaries.
Teleo was acquired by Havoc in 2026.
SpectrumAi is a digital health company innovating Autism care to increase access to high-quality ABA therapy for kids on the spectrum around the world. With support from industry veterans in technology and healthcare, SpectrumAi is working with global clinical leaders in ABA therapy, parents, and payers to modernize. SpectrumAi was acquired by CentralReach in 2025.
Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. The company leverages a best-in-class, fully integrated biotechnology platform for the discovery, development, and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in the veterinary species. In July 2024, Invetx was acquired by Dechra Pharmaceuticals Limited (Dechra), a global specialist veterinary pharmaceuticals business.
Blue Rabbit is a chronic disease management platform designed to coordinate diagnostics, medications and nutrition for animal patients. The company enables the effortless administration of healthcare through an ecosystem of technology driven solutions and services.